Proteomics and heart disease: identifying biormarkers of clinical utility

被引：40

作者：

Fu, Qin

Van Eyk, Jennifer E.

机构：

[1] Johns Hopkins Univ, Biomarker Dev Program, Baltimore, MD 21224 USA

[2] Johns Hopkins Univ, Hopkins Bayview Proteom Ctr, Baltimore, MD 21224 USA

[3] Johns Hopkins Univ, NHLBI Proteom Grp, Baltimore, MD 21224 USA

[4] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21224 USA

[5] Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21224 USA

来源：

EXPERT REVIEW OF PROTEOMICS | 2006年 / 3卷 / 02期

关键词：

2D electrophoresis; biomarker candidate; cardiovascular disease; glycome; interactome; multidimensional liquid chromatography; multiplex immune assay; peptidome; plasma; proteomic pattern; proteomics; serum; subproteome;

D O I：

10.1586/14789450.3.2.237

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Cardiovascular disease is the leading cause of mortality and morbidity in the industrialized world. Total worldwide deaths due to this disease are currently estimated at 17 million per year, and this number is expected to increase over the next several decades. To address this epidemic, a major effort has begun to develop new cardiovascular disease markers through the use of proteomic analysis, the global study of proteins. This review discusses strategies, recent technological advances and other issues in plasma/serum biomarker discovery for cardiovascular diseases. Emphasis lies on the needs for standardizing specimen collection, methods for reducing plasma proteome complexity to subproteomes, selection of appropriate technology platforms and strategies to evaluate candidates by multiplexed immune assays. The overall goal of this effort is to identify serum biomarkers for diagnosis, therapeutic monitoring and risk stratification of cardiovascular diseases.

引用

页码：237 / 249

页数：13

共 82 条

[21] Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: Systematic variation between sample types and calibration of mass spectrometry data [J].